Product Description
An Alphaviral Vector Encoding The HER2 Extracellular Domain And Transmembrane Region. The vaccine is based on a virus called Venezuelan equine encephalitis but it has been changed so it cannot cause active infection. Instead, the virus has been changed so it tells the immune system to attack cancer cells which make HER2. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01526473)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: H. Kim Lyerly
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Cancer
Phase 1: Ovarian Cancer|Breast Cancer|Encephalitis, Viral|Gastrointestinal Cancer|Lung Cancer|Pancreatic Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01526473 |
Pro00034612 | P1 |
Completed |
Encephalitis, Viral|Ovarian Cancer|Breast Cancer|Pancreatic Cancer|Lung Cancer|Gastrointestinal Cancer |
2016-03-01 |
2019-03-19 |
Treatments |
|
NCT03632941 |
Pro00100093 | P2 |
Terminated |
Breast Cancer |
2023-09-03 |
2026-06-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|